Westend S.A.
CIK 1283968 · last filed 2024-03-25
Westend S.A. is a corporate insider who has filed 11 SEC Form 4 insider transactions across 6 companies since 2007. The most recent filing shows the insider sold $132.5M of CAVA on Mar 25, 2024. Across all open-market trades the lifetime net is −$1.26B, making them a net seller over the disclosed history. Current disclosed insider exposure totals $6.95B across reported positions. The firm reports its address in Luxembourg, N4. 75 SEC filings were submitted jointly with Artal Group S.A.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
WTW price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
44, RUE DE LA VALLEE
LUXEMBOURG, N4 L-2661
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| CAVA | Director | 26,507,990 | $61.20 | $1.62B | -$132.50M | 2 | 2024-03-25 |
| CRESCENT BIOPHARMA, INC. (GLYC) Delisted | 10%+ Owner | 85,891 | $15.70 | $1.35M | $170.0K | 1 | 2023-02-28 |
| SRRK | 10%+ Owner | 8,784,005 | $50.26 | $441.44M | $759.5K | 1 | 2022-10-07 |
| WTW | 10%+ Owner | 14,818,300 | $329.14 | $4.88B | -$1.14B | 5 | 2018-08-16 |
| LXRX | Director | 2,399,859 | $1.84 | $4.42M | $5.00M | 1 | 2018-06-04 |
| Ceres, Inc. (CERE) Delisted | Director | 524,021 | $44.96 | $23.56M | $0 | 1 | 2012-11-13 |
Recent Filings
11 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2024-03-25 | CAVA | Sell (S) | −2,000,000 | -$132.50M | EDGAR |
| 2023-06-22 | CAVA | Exer (M) | +32,007,990 | $0 | EDGAR |
| 2023-02-28 | CRESCENT BIOPHARMA, INC. (GLYC) Delisted | Buy (P) | +100,000 | $170.0K | EDGAR |
| 2022-10-07 | SRRK | Buy (P) | +99,971 | $759.5K | EDGAR |
| 2018-08-16 | WTW | Sell (S) | −6,000,000 | -$456.00M | EDGAR |
| 2018-06-04 | LXRX | Buy (P) | +416,481 | $5.00M | EDGAR |
| 2014-08-19 | WTW | Buy (P) | +51,790 | $1.21M | EDGAR |
| 2014-08-06 | WTW | Buy (P) | +257,841 | $5.57M | EDGAR |
| 2012-11-13 | Ceres, Inc. (CERE) Delisted | Other (J) | +135,232 | $654.5K | EDGAR |
| 2011-02-28 | WTW | Sell (S) | −2,000,000 | -$121.50M | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.